Roche and Biogen Idec discontinue ocrelizumab for RA
This article was originally published in Scrip
Executive Summary
Roche and Biogen Idec have discontinued the Phase III development of their humanised anti-CD20 monoclonal antibody ocrelizumab for rheumatoid arthritis (RA) after deciding it has an unfavourable risk:benefit profile.